Literature DB >> 18059258

Brief report: respiratory syncytial virus activity--United States, July 2006-November 2007.

.   

Abstract

Respiratory syncytial virus (RSV), the most common cause of severe lower respiratory tract disease among infants and young children, typically infects persons by age 2 years and can cause subsequent infections throughout life. RSV infection primarily manifests as bronchiolitis or pneumonia and results in approximately 75,000 to 125,000 hospitalizations in the United States each year. Persons at increased risk for severe disease or death include premature infants, older adults, and persons of any age with compromised respiratory, cardiac, or immune systems. RSV is transmitted from person to person via close contact, droplets, or fomites. In temperate climates, peak RSV activity typically occurs during the winter. However, year-to-year national and regional variability in the RSV season onset and offset occurs in the United States. RSV circulation also varies by geographic location; for example, Florida has an earlier season onset and a longer season than the rest of the United States. Using data reported to the National Respiratory and Enteric Virus Surveillance System (NREVSS), this report summarizes RSV temporal and geographic trends in the United States during the weeks ending July 8, 2006-June 30, 2007, and for the first 5 months of the current reporting season (the weeks ending July 7-November 24, 2007). Appropriately timed diagnostic tests can provide data that indicate when the RSV season begins nationally and regionally, information that has been critical in determining when to begin RSV prophylaxis for infants and children at high risk for infection.

Entities:  

Mesh:

Year:  2007        PMID: 18059258

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  7 in total

1.  Effect of young sibling visitation on respiratory syncytial virus activity in a NICU.

Authors:  A M Peluso; B A Harnish; N S Miller; E R Cooper; A M Fujii
Journal:  J Perinatol       Date:  2015-04-02       Impact factor: 2.521

2.  Respiratory syncytial virus: diagnosis, treatment and prevention.

Authors:  Lea S Eiland
Journal:  J Pediatr Pharmacol Ther       Date:  2009-04

3.  RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.

Authors:  Wenliang Zhang; Ralph A Tripp
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

Review 4.  Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma.

Authors:  Shyam S Mohapatra; Sandhya Boyapalle
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

5.  Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection.

Authors:  Andres Pelaez; G Marshall Lyon; Seth D Force; Allan M Ramirez; David C Neujahr; Marianne Foster; Priyumvada M Naik; Anthony A Gal; Patrick O Mitchell; E Clinton Lawrence
Journal:  J Heart Lung Transplant       Date:  2009-01       Impact factor: 10.247

6.  Infection and maturation of monocyte-derived human dendritic cells by human respiratory syncytial virus, human metapneumovirus, and human parainfluenza virus type 3.

Authors:  Cyril Le Nouën; Shirin Munir; Stéphanie Losq; Christine C Winter; Thomas McCarty; David A Stephany; Kevin L Holmes; Alexander Bukreyev; Ronald L Rabin; Peter L Collins; Ursula J Buchholz
Journal:  Virology       Date:  2009-01-06       Impact factor: 3.616

7.  Viral etiology of respiratory infections in children under 5 years old living in tropical rural areas of Senegal: The EVIRA project.

Authors:  Mbayame Ndiaye Niang; Ousmane M Diop; Fatoumata Diene Sarr; Deborah Goudiaby; Hubert Malou-Sompy; Kader Ndiaye; Astrid Vabret; Laurence Baril
Journal:  J Med Virol       Date:  2010-05       Impact factor: 2.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.